RMD vs. SYK, MDT, BDX, EW, IDXX, DXCM, STE, PODD, BAX, and HOLX
Should you be buying ResMed stock or one of its competitors? The main competitors of ResMed include Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), DexCom (DXCM), STERIS (STE), Insulet (PODD), Baxter International (BAX), and Hologic (HOLX). These companies are all part of the "health care equipment" industry.
ResMed vs. Its Competitors
ResMed (NYSE:RMD) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, community ranking, media sentiment, institutional ownership, profitability and dividends.
ResMed has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.
ResMed pays an annual dividend of $2.12 per share and has a dividend yield of 0.8%. Stryker pays an annual dividend of $3.36 per share and has a dividend yield of 0.9%. ResMed pays out 23.8% of its earnings in the form of a dividend. Stryker pays out 45.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. ResMed has raised its dividend for 13 consecutive years and Stryker has raised its dividend for 32 consecutive years. Stryker is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
ResMed currently has a consensus target price of $259.33, indicating a potential upside of 3.25%. Stryker has a consensus target price of $427.30, indicating a potential upside of 12.14%. Given Stryker's stronger consensus rating and higher possible upside, analysts clearly believe Stryker is more favorable than ResMed.
Stryker has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.
Stryker received 500 more outperform votes than ResMed when rated by MarketBeat users. Likewise, 64.42% of users gave Stryker an outperform vote while only 52.58% of users gave ResMed an outperform vote.
ResMed has a net margin of 25.34% compared to Stryker's net margin of 13.25%. ResMed's return on equity of 26.17% beat Stryker's return on equity.
55.0% of ResMed shares are owned by institutional investors. Comparatively, 77.1% of Stryker shares are owned by institutional investors. 0.7% of ResMed shares are owned by insiders. Comparatively, 5.9% of Stryker shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Stryker had 21 more articles in the media than ResMed. MarketBeat recorded 35 mentions for Stryker and 14 mentions for ResMed. Stryker's average media sentiment score of 1.46 beat ResMed's score of 1.07 indicating that Stryker is being referred to more favorably in the news media.
Summary
Stryker beats ResMed on 15 of the 22 factors compared between the two stocks.
Get ResMed News Delivered to You Automatically
Sign up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NYSE:RMD) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy RMD Stock Free RMD Stock Alerts